Dacomitinib

Dacomitinib

Names
IUPAC name (2E)-N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl}-4-(1-piperidinyl)-2-butenamide
Other names PF-00299804
Identifiers
CAS Number	1110813-31-4 Y
3D model (JSmol)	Interactive image
ChEBI	CHEBI:132268
ChemSpider	9685914
IUPHAR/BPS	7422
KEGG	D09883
PubChem CID	11511120
UNII	2XJX250C20 Y
InChI InChI=1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+ Key: LVXJQMNHJWSHET-AATRIKPKSA-N InChI=1/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+ Key: LVXJQMNHJWSHET-AATRIKPKBC
SMILES COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)/C=C/CN4CCCCC4
Properties
Chemical formula	C24H25ClFN5O2
Molar mass	469.95 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Dacomitinib (PF-00299804) is an experimental drug candidate under development by Pfizer for the treatment of non-small-cell lung carcinoma (NSCLC). It is a selective and irreversible inhibitor of EGFR.

Dacomitinib has advanced to several Phase III clinical trials. The Jan 2014 results of the first trials were disappointing, with a failure to meet the study goals, Additional Phase III trials are ongoing.

In 2017 results of a trial comparing dacomitinib to gefitinib for NSCLC (driven by mutated EGFR) were announced.